ReviewFrontiers in pharmacology2026
Oral plant-derived exosome-like nanovesicles: a new therapeutic perspective for intestinal diseases.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicle-based therapies in IBD: immunomodulation, regeneration, and translation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant-derived exosome-like nanovesicles (PELNs) are a class of nanoscale vesicles isolated from plant cells. They are enriched with proteins, lipids, nucleic acids and other bioactive components, and are capable of exerting diverse biological effects. Due to their efficient absorption and transformation, PELNs when administered orally, demonstrate significant therapeutic efficacy for treating various gastrointestinal diseases, including inflammatory bowel disease, intestinal tumors, and gut dysbiosis. Despite growing evidence highlighting their promise as emerging biotherapeutic agents for intestinal disorders, challenges still persist due to poorly defined mechanisms of action and limited clinical experience. This review summarizes the characteristics of PELNs, the advantages of their oral delivery, and current engineering strategies. It further explores the mechanisms through which PELNs promote intestinal health and analyzes their clinical prospects and challenges. The review aims to provide insights for future research and clinical translation, thereby facilitating the advancement of PELN-based therapies for gastrointestinal diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.